ReNeuron is a leading, UK-based stem cell company. Our primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.

We have received regulatory and conditional ethical approvals to commence a ground-breaking Phase I clinical trial in the UK with our lead ReN001 stem cell therapy for disabled stroke patients. We are developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.